PTC Therapeutics, Inc. (PTCT) Balance Sheet

The move from roughly -$1.1B to -$191.2M equity over eight quarters suggests that earnings or capital actions have partially offset prior accumulated losses, with retained earnings still near -$2.9B. Total liabilities of $3.4B continue to exceed total assets of $3.2B, which may indicate that improvement is driven by episodic gains rather than a durable shift in capital structure. Investors should monitor whether equity turns sustainably positive before treating the trajectory as strengthening.

The drop from $2.5B to roughly $400M in early 2025 suggests a large repayment or reclassification, while the subsequent rebound to $696.5M may reflect new financing taken on to fund operations. With debt-to-equity not meaningful given negative book equity, leverage is better judged by absolute debt against cash of $508.9M in 2026Q3, which warrants further investigation of maturity schedules. The reported figures alone do not reveal refinancing terms, so the sustainability of the current structure cannot be confirmed.

A current ratio above 3 appears comfortable on the surface, but the roughly $1.0B decline in cash across six quarters indicates that liquidity is being consumed faster than it is replenished. The cash position of $508.9M relative to total liabilities of $3.4B suggests limited buffer against operating shocks. Investors should monitor the pace of cash burn against the remaining cash balance to assess runway.

The near-elimination of deferred revenue suggests that prior collaboration or licensing payments have largely been recognized, with minimal upfront cash committed for future periods. This reduces visibility into forward top-line performance, since revenue appears to depend on new agreements rather than existing backlog. The absence of meaningful deferred revenue implies that the business may need fresh deal flow to sustain reported income.